The FDA has granted accelerated approval to AstraZeneca's Etcamah (camizestrant), used with a CDK 4/6 inhibitor, for breast cancer.

The FDA has so far approved four botanical products, with a view to greenlight more. Credit: Svetliy/Shutterstock.com. The US Food and Drug Administration (FDA) is requesting public input on both the ...

Ionis claims Zanvastro will become available to US patients with rare neurodegenerative condition, Alexander disease “in the coming weeks”.

The FDA's latest efforts to curb the illicit US medicines trade are primarily centred around weight loss and fat-reducing peptides.

Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of subcutaneous drug formulations using Alteogen’s ALT-B4 technology.

Eli Lilly has once again returned to the M&A table, striking a $2.875bn agreement to buy autoimmune and allergic disease drug developer Merida Biosciences. The deal for Merida, wh ...

These White House deals will require the nine midsize pharma companies to provide MFN prices to state Medicaid programmes nationally.

Typewriter harnesses a non-viral approach as viral vectors increasingly come under the spotlight for their associated safety risks.

The US FDA has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).

KOLs interviewed by GlobalData consistently recognized tirzepatide's cardiometabolic value as extending well beyond weight loss alone.

At ESC 2026, a session presented by Dr Domenica Rubino covered the considerations to take into account when comparing oral and injectable formulations of GLP-1 therapies.